This mechanism contrasts with that of biological disease modifying drugs, which are monoclonal antibodies targeted against only one or two specific cytokines, such as TNF-α, IL-23 or IL-17 blockers for psoriasis or IL-4 and IL-13 inhibitors for atopic dermatitis. Here, IL17A is linked to psoriasis.